{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:18:26Z","timestamp":1791317906571,"version":"4.3.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejphar.2020.173741","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T04:47:17Z","timestamp":1605847637000},"page":"173741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["A comprehensive review on potential therapeutics interventions for COVID-19"],"prefix":"10.1016","volume":"890","author":[{"given":"Heerak","family":"Chugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amardeep","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh K.","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7492-225X","authenticated-orcid":false,"given":"Gagan","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173741_bib2","unstructured":"CSIR-CDRI\u2019s COVID-19 drug candidate Umifenovir secures DCGI approval for phase III clinical trial (2020) Available at: https:\/\/www.csir.res.in\/slider\/csir-cdri%E2%80%99s-covid-19-drug-candidate-umifenovir-secures-dcgi-approval-phase-iii-clinical-trial (accessed 26 June, 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib3","unstructured":"(ox.ac.uk, 2020) Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19. Available at: http:\/\/www.ox.ac.uk\/news\/2020-06-16-dexamethasone-reduces-death-hospitalised-patients-severe-respiratory-complications (accessed on 1st July 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib4","unstructured":"Government Measures_Taken_in_Response_to_COVID-19.pdf. Available at: https:\/\/www.thompsonhine.com\/uploads\/1345\/doc\/Country-by-Country_Guide. (accessed on 28 June, 2020)."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173741_bib7","unstructured":"RDIF and ChemRar announce the Russian Ministry ofHealth has included Avifavir in the list of nationally recommended drugs for the treatment of COVID-19. https:\/\/rdif.ru\/Eng_fullNews\/5224\/ (accessed on 4th June 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib8","unstructured":"Rigel launches Phase II trial to access fostamatinib for Covid-19 patients https:\/\/www.clinicaltrialsarena.com\/news\/glenmark-favipiravir-combo-trial. (accessed on 4th July 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib9","series-title":"The treatment and outcomes of patients with COVID-19 in Hubei, China: a multi-centered, retrospective, observational study","author":"Shang","year":"2020"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008536","article-title":"The hallmarks of COVID-19 disease","volume":"16","author":"Tang","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2020.173741_bib10","unstructured":"(ema.europa.eu, 2020) Summary on compassionate use. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use remdesivirgi lead_en.pdf. (accessed on 29 April 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib12","unstructured":"The Best Global Responses to COVID-19 Pandemic. Available at: https:\/\/time.com\/5851633\/best-global-responses-covid-19\/ (accessed on 28 June, 2020)."},{"key":"10.1016\/j.ejphar.2020.173741_bib13","series-title":"Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China","author":"Wang","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib14","unstructured":"WHO, 2020c World Health Organization, 2020. DRAFT landscape of COVID-19 candidate vaccines. World."},{"key":"10.1016\/j.ejphar.2020.173741_bib15","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"20","key":"10.1016\/j.ejphar.2020.173741_bib16","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejphar.2020.173741_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2020.03.022","article-title":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak","author":"Zhang","year":"2020","journal-title":"Curr. Biol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173741_bib18","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/med.21315","article-title":"Recent advances on plasmin inhibitors for the treatment of fibrinolysis\u2010related disorders","volume":"34","author":"Al\u2010Horani","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib20","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","author":"Arabi","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.06.099","article-title":"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","author":"Arshad","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173741_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/pathogens9030186","article-title":"Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks","volume":"9","author":"Ashour","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.ejphar.2020.173741_bib23","series-title":"Ministry of Ayush 2020. Guidelines for Ayurveda Practitioners for COVID 19","year":"2020"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2344\/0003-3006-60.1.25","article-title":"Basic and clinical pharmacology of glucocorticosteroids","volume":"60","author":"Becker","year":"2013","journal-title":"Anesth. Prog."},{"key":"10.1016\/j.ejphar.2020.173741_bib26","article-title":"Ueber das zustandekommen der diphtherie-immunit\u00e4t und der tetanus-immunit\u00e4t bei thieren","author":"Behring","year":"1890","journal-title":"mBio"},{"key":"10.1016\/j.ejphar.2020.173741_bib27","article-title":"Global spread of SARS-CoV-2 subtype with spike protein mutation D614G is shaped by human genomic variations that regulate expression of TMPRSS2 and MX1 genes","author":"Bhattacharyya","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejphar.2020.173741_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173741_bib29","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2020.173741_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030841","article-title":"Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19)","author":"Brake","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.ejphar.2020.173741_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173741_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejphar.2020.173741_bib35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","article-title":"Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2020.173741_bib36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3389\/fonc.2019.00852","article-title":"The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"issue":"6489","key":"10.1016\/j.ejphar.2020.173741_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aba9757","article-title":"The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak","volume":"368","author":"Chinazzi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173741_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.ejphar.2020.173741_bib42","series-title":"An Open Study of the Safety","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib45","series-title":"An Open Study of the Safety, Tolerability and Immunogenicity of \"Gam-COVID-Vac Lyo\" Vaccine against COVID-19-","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib54","series-title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib72","series-title":"The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib78","series-title":"Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients with Pneumonia by COVID-19","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib81","series-title":"Severe 2019-nCoV Remdesivir RCT - Full Text View - ClinicalTrials.Gov","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1579-0","article-title":"RNA viruses promote activation of the NLRP3 inflammasome through cytopathogenic effect-induced potassium efflux","volume":"10","author":"da Costa","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2020.173741_bib117","article-title":"A trial of lopinavir\u2013ritonavir in covid-19","author":"Dalerba","year":"2020","journal-title":"J Heart Lung Transplant. N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib118","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.0c00233","article-title":"Quest for a COVID-19 cure by repurposing small molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply","author":"De Savi","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejphar.2020.173741_bib119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173741_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019\u2010nCoV infection","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.ejphar.2020.173741_bib121","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173741_bib122","series-title":"COVID-19) Vaccine Candidate with CpG 1018 Adjuvant","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib123","doi-asserted-by":"crossref","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: faraway, so close","author":"Favalli","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2020.173741_bib124","series-title":"Letter Revoking EUA for Chloroquine Phosphate and Hydroxychloroquine Sulfate, 6\/15\/2020","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib125","series-title":"Drug Trials Snapshots: Olumiant","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib126","series-title":"US Food & Drug Administration Development & Approval Process (CBER) Investigational COVID-19 Convalescent Plasma - Emergency INDs","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib127","series-title":"Analogue-based Drug Discovery","year":"2010"},{"key":"10.1016\/j.ejphar.2020.173741_bib128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173741_bib129","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173741_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173741_bib131","article-title":"The new pandemic covid-19: treatment options and developments","volume":"113","author":"Gayatri","year":"2020","journal-title":"Asian J. Bio. Sci."},{"key":"10.1016\/j.ejphar.2020.173741_bib133","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib134","article-title":"Ayurvedic Treatment of COVID-19\/SARS-CoV-2: a case report","author":"Girija","year":"2020","journal-title":"J. Ayurveda Integr. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib137","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib138","doi-asserted-by":"crossref","DOI":"10.1152\/physiolgenomics.00033.2020","article-title":"Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease","author":"Golonka","year":"2020","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejphar.2020.173741_bib139","article-title":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses\u2013a statement of the Coronavirus Study Group","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejphar.2020.173741_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173741_bib141","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2020.173741_bib142","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/cid\/cir398","article-title":"Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection","volume":"53","author":"Han","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib143","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41575-020-0295-7","article-title":"COVID-19: faecal\u2013oral transmission","volume":"17","author":"Hindson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2020.173741_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2020.173741_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ejphar.2020.173741_bib147","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","article-title":"Cellular entry of the SARS coronavirus","volume":"12","author":"Hofmann","year":"2004","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejphar.2020.173741_bib148","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.ejphar.2020.173741_bib149","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2174\/138161207782794248","article-title":"Strategies of development of antiviral agents directed against influenza virus replication","volume":"13","author":"Hsieh","year":"2007","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2020.173741_bib150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","article-title":"Evaluation of metal\u2010conjugated compounds as inhibitors of 3CL protease of SARS\u2010CoV","volume":"574","author":"Hsu","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2020.173741_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.08.001","article-title":"Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019","author":"Igbinosa","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejphar.2020.173741_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2020.04.007","article-title":"Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases","author":"Iwabuchi","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.ejphar.2020.173741_bib153","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 preliminary report","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib154","article-title":"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China","author":"Jian-ya","year":"2020","journal-title":"medRxivb"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173741_bib155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173741_bib156","article-title":"Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning","author":"Kadioglu","year":"2020","journal-title":"Bull. World Health Organ. Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib157","doi-asserted-by":"crossref","first-page":"2","DOI":"10.22502\/jlmc.v8i1.335","article-title":"\u201cSolidarity trial\u201d: a feeling of trust towards COVID-19 treatments","volume":"8","author":"Karki","year":"2020","journal-title":"J. Lumbini Med. Coll."},{"issue":"12","key":"10.1016\/j.ejphar.2020.173741_bib158","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173741_bib159","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","article-title":"Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-\u03b1 for middle east respiratory syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejphar.2020.173741_bib160","first-page":"1","article-title":"Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejphar.2020.173741_bib161","first-page":"1","article-title":"Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173741_bib162","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X16687481","article-title":"Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential","volume":"9","author":"Kuriya","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.ejphar.2020.173741_bib163","series-title":"Launch of a European Clinical Trial against COVID-19","year":"2020"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib164","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib165","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173741_bib166","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2020.173741_bib167","first-page":"1","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib168","doi-asserted-by":"crossref","first-page":"105941","DOI":"10.1016\/j.rmed.2020.105941","article-title":"Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)","volume":"167","author":"Lippi","year":"2020","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib169","first-page":"505","article-title":"No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2. Emerg","volume":"9","author":"Liu","year":"2020","journal-title":"Microb. Infect."},{"issue":"10224","key":"10.1016\/j.ejphar.2020.173741_bib170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ejphar.2020.173741_bib171","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib172","article-title":"Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","author":"Madariaga","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ejphar.2020.173741_bib173","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01648-20","article-title":"The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells","author":"Matsuyama","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2020.173741_bib174","first-page":"1","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2020.173741_bib176","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-0290-0","article-title":"Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","author":"Nguyen","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2020.173741_bib177","doi-asserted-by":"crossref","unstructured":"O'Meara, M.J., Guo, J.Z., Swaney, D.L., Tummino, T.A. and H\u00fcttenhain, R., A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nature. doi: 10.1038\/s41586-020-2286-9.","DOI":"10.1038\/s41586-020-2286-9"},{"key":"10.1016\/j.ejphar.2020.173741_bib178","doi-asserted-by":"crossref","first-page":"d204","DOI":"10.2741\/okuno","article-title":"Retinoids in liver fibrosis and cancer","volume":"7","author":"Okuno","year":"2002","journal-title":"Front. Biosci."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib179","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"Oldfield","year":"2009","journal-title":"Tocilizumab. Drugs"},{"key":"10.1016\/j.ejphar.2020.173741_bib180","doi-asserted-by":"crossref","first-page":"912A","DOI":"10.1378\/chest.1110134","article-title":"Preadmission use of inhaled corticosteroids is associated with a reduced risk of direct acute lung injury\/acute respiratory distress syndrome","volume":"140","author":"Ortiz-Diaz","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2020.173741_bib181","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/376327","article-title":"Indian traditional ayurvedic system of medicine and nutritional supplementation","author":"Pandey","year":"2013","journal-title":"Evid Based Complement Alternat. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib182","series-title":"Potential Therapeutic Targets for Combating SARS-CoV-2: Drug Repurposing, Clinical Trials and Recent Advancements","first-page":"117883","author":"Pandey","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","author":"Phillips","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib185","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2020.173741_bib186","series-title":"Chemokines in COVID-19 Patients: A Systematic Review and Meta-Analysis","article-title":"Evaluation of blood levels of cytokines\/chemokines in COVID-19 patients: a systematic review and meta-analysis","author":"Ramezani","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib187","series-title":"No Clinical Benefit from Use of Hydroxychloroquine in Hospitalised Patients with COVID-19. 5 June 2020","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib190","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ejphar.2020.173741_bib191","article-title":"Development of remdesivir as a dry powder for inhalation by thin film freezing","author":"Sahakijpijarn","year":"2020","journal-title":"bioRxiv"},{"issue":"18","key":"10.1016\/j.ejphar.2020.173741_bib192","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.ejphar.2020.173741_bib193","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173741_bib194","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID\u201019: what's next?","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2020.173741_bib196","series-title":"Inhaled Corticosteroid Use and Risk COVID-19 Related Death Among 966,461 Patients with COPD or Asthma: an OpenSAFELY Analysis. medRxiv","author":"Schultze","year":"2020"},{"issue":"21","key":"10.1016\/j.ejphar.2020.173741_bib197","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173741_bib198","article-title":"Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2","author":"Sharma","year":"2020","journal-title":"ChemRxiv"},{"issue":"396","key":"10.1016\/j.ejphar.2020.173741_bib199","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"16","key":"10.1016\/j.ejphar.2020.173741_bib200","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173741_bib201","first-page":"1","article-title":"A review of coronavirus disease-2019 (COVID-19)","author":"Singhal","year":"2020","journal-title":"Indian J. Pediatr."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib202","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002009","article-title":"Correction: experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2020.173741_bib204","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib205","first-page":"1","article-title":"HMGB1: a possible crucial therapeutic target for COVID-19?","author":"Street","year":"2020","journal-title":"Horm Res. Paediatr."},{"key":"10.1016\/j.ejphar.2020.173741_bib206","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","author":"Tang","year":"2020","journal-title":"Natl. Sci. Rev"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib207","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173741_bib208","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/acm.2020.0129","article-title":"Public health approach of Ayurveda and Yoga for COVID-19 prophylaxis","volume":"26","author":"Tillu","year":"2020","journal-title":"Altern. Complement. Med."},{"key":"10.1016\/j.ejphar.2020.173741_bib209","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"Van Doremalen","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.1.5.9497","article-title":"September. Tocilizumab","volume":"5","author":"Venkiteshwaran","year":"2009","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.ejphar.2020.173741_bib212","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2020.173741_bib213","series-title":"Coronavirus Disease (COVID-19)","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173741_bib215","doi-asserted-by":"crossref","DOI":"10.1111\/anae.15093","article-title":"Airborne transmission of severe acute respiratory syndrome coronavirus\u20102 to healthcare workers: a narrative review","author":"Wilson","year":"2020","journal-title":"Anaesthesia"},{"key":"10.1016\/j.ejphar.2020.173741_bib216","series-title":"Modes of Transmission of Virus Causing COVID-19: Implications for IPC Precaution Recommendations: Scientific Brief","year":"2020"},{"issue":"10228","key":"10.1016\/j.ejphar.2020.173741_bib217","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30557-2","article-title":"SARS-CoV-2 is an appropriate name for the new coronavirus","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib218","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Med"},{"key":"10.1016\/j.ejphar.2020.173741_bib219","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.resinv.2019.12.005","article-title":"Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells","volume":"58","author":"Yamaya","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.ejphar.2020.173741_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104820","article-title":"Chemical composition and pharmacological mechanism of Qingfei Paidu decoction and Ma xing Shi Gan decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study","author":"Yang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173741_bib221","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infectious Dis."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173741_bib222","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173741_bib223","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","article-title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus","volume":"18","author":"Zhang","year":"2020","journal-title":"J Integr Med"},{"key":"10.1016\/j.ejphar.2020.173741_bib224","first-page":"2020030065","article-title":"Short-term moderate-dose corticosteroid plus immunoglobulin effectively reverses COVID-19 patients who have failed low-dose therapy","author":"Zhou","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.ejphar.2020.173741_bib225","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173741_bib189","unstructured":"(gilead.com, 2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. doi: 10.1021\/acscentsci.0c00489 . Available at: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/6\/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19. (accessed on 29th June 2020)."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920308335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920308335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:11:31Z","timestamp":1762143091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920308335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":145,"alternative-id":["S0014299920308335"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173741","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review on potential therapeutics interventions for COVID-19","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173741"}}